Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CPT-11. The European experience.
Armand JP, Terret C, Couteau C, Rixe O. Armand JP, et al. Among authors: terret c. Ann N Y Acad Sci. 1996 Dec 13;803:282-91. doi: 10.1111/j.1749-6632.1996.tb26398.x. Ann N Y Acad Sci. 1996. PMID: 8993522 Review.
CPT-11: the European clinical development.
Terret C, Couteau C, Armand JP. Terret C, et al. J Infus Chemother. 1996 Summer;6(3):152-7. J Infus Chemother. 1996. PMID: 9229329 Review.
Dose and time dependencies of 5-fluorouracil pharmacokinetics.
Terret C, Erdociain E, Guimbaud R, Boisdron-Celle M, McLeod HL, Féty-Deporte R, Lafont T, Gamelin E, Bugat R, Canal P, Chatelut E. Terret C, et al. Clin Pharmacol Ther. 2000 Sep;68(3):270-9. doi: 10.1067/mcp.2000.109352. Clin Pharmacol Ther. 2000. PMID: 11014408 Clinical Trial.
Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG).
Terret C, Zanetta S, Roché H, Schellens JH, Faber MN, Wanders J, Ravic M, Droz JP; EORTC Early Clinical Study Group. Terret C, et al. Eur J Cancer. 2003 May;39(8):1097-104. doi: 10.1016/s0959-8049(03)00128-x. Eur J Cancer. 2003. PMID: 12736109 Clinical Trial.
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Perez Gracia JL, Stephen Hodi F, Taus A, Martinez Garcia M, Boni V, Eder JP, Hafez N, Sullivan R, Mcdermott D, Champiat S, Aspeslagh S, Terret C, Jegg AM, Jacob W, Cannarile MA, Ries C, Korski K, Michielin F, Christen R, Babitzki G, Watson C, Meneses-Lorente G, Weisser M, Rüttinger D, Delord JP, Marabelle A. Gomez-Roca C, et al. Among authors: terret c. J Immunother Cancer. 2022 May;10(5):e004076. doi: 10.1136/jitc-2021-004076. J Immunother Cancer. 2022. PMID: 35577503 Free PMC article. Clinical Trial.
67 results